Anoro Ellipta is delivered in the easy-to-use Ellipta inhaler device1-3

Help your patients with their inhaler technique by ordering a demonstration device

Anoro Ellipta dosing: The recommended (and maximum) dose is one inhalation of Anoro Ellipta (UMEC/VI 55/22 micrograms) once daily.
The dose should be administered at the same time of the day each day to maintain bronchodilation.
Please refer to the SmPC for further information prior to prescribing.

Click on the video below to see how to use the Ellipta inhaler

An easy-to-use COPD inhaler can help your patient receive the right dose1-3

Poor inhaler technique could be a reason why a patient's COPD symptoms are poorly controlled.3

In a single-visit, open-label, crossover study, significantly fewer COPD patients made a critical error* with the Ellipta inhaler compared with other commonly used COPD inhalers (Accuhaler, MDI, Turbohaler, HandiHaler, Breezhaler) after reading the patient information leaflet (PIL); (p<0.001 for all comparisons).**1

*A critical error is defined as those likely to result in the inhalation of significantly reduced, minimal or no medication.1

% of patients making ≥ one critical error after reading the PIL with Ellipta vs. HandiHaler**1
Ellipta vs. Handihaler critical errors graph

3.4x fewer patients made a critical error* with Ellipta vs. HandiHaler

(Ellipta 14% (17/118); HandiHaler 48% (57/118); p<0.001)

**This was a multi-centre, single visit, randomised, open-label, cross-over study to investigate errors in the use of different inhalers in patients with COPD. Patients were randomised to receive either Ellipta or another commonly used COPD inhaler (Accuhaler, MDI, Turbohaler, HandiHaler, Breezhaler). Patients were naive to the inhalers under investigation in their study arm.1

Support your patients starting on Anoro Ellipta maintenance therapy


  1. van der Palen J et al. NPJ Prim Care Respir Med 2016;26:16079.
  2. Svedsater H et al. BMC Pulm Med 2013;13:72–86.
  3. Riley JH et al. Int J Chron Obstruct Pulm Dis 2016;11:1873–1880.

Adverse events should be reported. Reporting forms and information can be found at
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.

© 2021 GSK group of companies or its licensor. ANORO was developed in collaboration with INNOVIVA.
Trademarks are owned by or licensed to the GSK group of companies.

Innoviva Logo

PM-GB-UCV-WCNT-200039 V2.0 June 2021